IBDoc® has now been on the market for over 2 years and it is transforming the way IBD patients manage their disease. IBDoc® is used by over a thousand patients in more than 15 countries and we now support 20 languages with Hebrew as the latest addition. BÜHLMANN as the only calprotectin company has been able
- support@ibdoc.net
- +41 61 487 12 12
- www.buhlmannlabs.ch
Blog Archives
Calprotectin: The Key to a Successful Treatment Pathway for IBD What is Inflammatory Bowel Disease? Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most
Continue Reading →
In December we received regulatory approval to expand the list of supported smartphones for IBDoc. To achieve this we established a thorough validation control to be able to include new smartphones. Since each smartphone model differs in camera and processor type, which relates to differences in measurement we always need to make sure that the supported
Interview with Dr. Christian Reinhard at UEGW 2016 about the first 18 months of market experience with IBDoc® At this year’s UEGW in Vienna, Dr. Christian Reinhard presented data collected from the first 18 months of market expirience with IBDoc®. In the biomarker session on Tuesday 18th of October the IBDoc® product manager at BÜHLMANN Laboratories
At the last European Crohn’s and Colitis Congress in Amsterdam we took the chance to record a video of our congress presence as well as a two interviews: One with an IBD Nurse, Anita Beyer, from the General Hospital in Vienna (AKH), who has been using IBDoc® since over one year and another interview with
At this year’s ECCO we took the chance to record an interview with Julia Edin, an IBD Patient from Oslo, who has been using IBDoc® for over a year:
At this year’s ECCO we took the chance to record an interview with Anita Beyer, an IBD Nurse in Vienna, who has been using IBDoc® for over a year:
At the last European Crohn’s and Colitis Congress in Amsterdam we took the chance to record a video of our congress presence as well as a two interviews: One with an IBD Nurse, Anita Beyer, from the General Hospital in Vienna (AKH), who has been using IBDoc® since over one year and another interview with
IBDoc® is now available in Australia. IBDoc® achieved the CE certification in April 2015 for self-testing making it available to patients throughout Europe. Now a second major milestone has been reached. The Australian Health Authorities TGA (Therapeutic Goods Administration), approved the use of IBDoc®. This means that IBDoc® can now be made available to all Australian IBD patients
In a recent article in the Journal of mHealth (Volume 3, Issue 3), McCombie and colleagues performed a systematic review of IBD symptom monitoring smartphone apps. They found 233 separate apps on Google Play Store (Android) and Apple App Store (iPhone) that matched their search criteria for IBD. Out of this inital apps they included